Clinical Trial Update: Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating sofosbuvir plus ribavirin with or without peginterferon alfa-2a in chronic hepatitis C patients who previously participated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-11-09